Market revenue in 2023 | USD 12.9 million |
Market revenue in 2030 | USD 40.3 million |
Growth rate | 17.7% (CAGR from 2023 to 2030) |
Largest segment | Services |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Services, NGS Commercial Software |
Key market players worldwide | Bio-Rad Laboratories Inc, DNAnexus, Qiagen NV, DNAstar, Pacific Biosciences of California Inc, Eurofins Scientific SE, Illumina Inc, PierianDx, Agilent Technologies Inc, Roche Holding AG, Alphabet Inc Class A, Thermo Fisher Scientific Inc, Golden Helix, Scigenom Labs, Genuity Science, Fabric Genomics (formerly Omicia), Congenica, Precigen |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to next-generation sequencing data analysis market will help companies and investors design strategic landscapes.
Services was the largest segment with a revenue share of 54.26% in 2023. Horizon Databook has segmented the Australia next-generation sequencing data analysis market based on services, ngs commercial software covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing awareness about the potential of gene therapy & cell-based therapy is expected to drive the Australia NGS data analysis market. Moreover, decreasing DNA/RNA sequencing cost and increasing sequencing throughput are some of the factors contributing to market growth.
Such high amount of data can be utilized to resolve large and complex biological questions with the help of data analysis platforms. Owing to limited bioinformatics tools and infrastructure, the government of Australia is actively taking certain measures to bridge the gap.
In September 2020, the Australian government provided a grant of USD 2.42 million to University of South Wales, Sydney's School of Medical Sciences, to expand its genome sequencing and data analysis facility. The university is collaborating with Illumina, Inc. to develop a genome platform for COVID-19 tracking.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia next-generation sequencing data analysis market , including forecasts for subscribers. This country databook contains high-level insights into Australia next-generation sequencing data analysis market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account